Cepheid Reports 2009 Second Quart...((loss) from operations $(2873)...),Health

Date:7/30/2009

(loss) from operations $(2,873) $(3,689) $(6,025) $(3,782) Net income (loss) $(6,779) $(7,695) $(14,381) $(9,713) Restructuring charge - - 747 - Stock compensation expense 4,128 3,707 7,550 6,968 Amortization of purchased intangible assets 412 286 809 572 ------- ------- ------- ------- Non-GAAP measure of net income (loss) $(2,239) $(3,702) $(5,275) $(2,173) Basic and diluted net income (loss) per share $(0.12) $(0.13) $(0.25) $(0.17) Restructuring charge - - 0.01 - Stock compensation expense 0.07 0.07 0.14 0.12 Amortization of purchased intangible assets 0.01 - 0.01 0.01 ------- ------- ------- ------- Non-GAAP measure of net income (loss) $(0.04) $(0.06) $(0.09) $(0.04) Shares used in computing basic and diluted net income (loss) per share 58,053 57,054 57,943 56,603 (1) See discussion in press release.

'/>"/>

SOURCE Cepheid Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results